Cargando…
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
INTRODUCTION: Geographic access to novel oncology therapies, and the extent to which it may vary by potential sites of care, regions, and population characteristics, is poorly understood. We examined how expanding access to chimeric antigen receptor (CAR) T cell therapy administration sites impacts...
Autores principales: | Snyder, Sophie, Chung, Karen C., Jun, Monika P., Gitlin, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408091/ https://www.ncbi.nlm.nih.gov/pubmed/34302277 http://dx.doi.org/10.1007/s12325-021-01838-z |
Ejemplares similares
-
Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
por: Lyman, Gary H., et al.
Publicado: (2020) -
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care
por: Snyder, Sophie, et al.
Publicado: (2021) -
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022) -
Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
por: Weinstock, Matt, et al.
Publicado: (2022) -
CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)